OBI-833


OBI-833

Active Immuno-oncology Therapy

A second generation active immuno-oncology therapy based on the Globo H antigen, OBI-833 completed the Dose Escalation Phase of its phase I clinical trial for safety, from which the Company designated one dosage and one cancer type for its Cohort Expansion Phase. In 2016, the US FDA permitted the Company to merge its OBI-833/834 phase I investigational new drug application (IND) application into a single OBI-833 IND. The Company plans to carry out an additional OBI-833/834 arm in this Cohort Expansion Phase using the chosen dosage and cancer type.